Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCCOverview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab) Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCCProgram faculty:Joseph W. Franses, MD, PhDAssistant Professor of MedicineSection of Hematology-OncologyUniversity of ChicagoChicago, IllinoisNeehar Parikh, MD, MSAssociate ProfessorLi Ka Shing Research Professor of HepatologyClinical Director of HepatologyMedical Director, Liver Tumor ProgramDivision of Gastroenterology & HepatologyUniversity of MichiganAnn Arbor, MichiganMark Yarchoan, MDAssociate ProfessorSidney Kimmel Comprehensive Cancer CenterJohns HopkinsBaltimore, Maryland Resources:To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic.

There are no comments yet.

Please log in to write the first comment.